Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fluphenazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 3/20 | 0.98 |
| ▸ | LMNA | P02545 | 7/20 | 1.00 |
| ▸ | MAPT | P10636 | 7/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 5/20 | 1.00 |
| ▸ | USP2 | O75604 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 5/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 5/20 | 1.00 |
| ▸ | MEN1 | O00255 | 4/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 4/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 1.00 |
| ▸ | RAD52 | P43351 | 4/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 3/20 | 1.00 |
| ▸ | GMNN | O75496 | 3/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 3/20 | 1.00 |
| ▸ | RECQL | P46063 | 2/20 | 1.00 |
| ▸ | UBE2N | P61088 | 2/20 | 1.00 |
| ▸ | GLA | P06280 | 1/20 | 1.00 |
| ▸ | GAA | P10253 | 1/20 | 1.00 |
| ▸ | TP53 | P04637 | 4/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluphenazine SCHEMBL2560022 | 1.00 | LMNA (1.00) | LMNAMAPTSMN1; SMN2NPSR1USP2 | |
| Fluphenazine SCHEMBL1496274 | 1.00 | LMNA (1.00) | LMNAMAPTSMN1; SMN2NPSR1USP2 | |
| Fluphenazine SCHEMBL29860638 | 1.00 | LMNA (1.00) | LMNAMAPTSMN1; SMN2NPSR1USP2 | |
| Fluphenazine SCHEMBL30390918 | 1.00 | LMNA (1.00) | LMNAMAPTSMN1; SMN2NPSR1USP2 | |
| Fluphenazine SCHEMBL41634 | 1.00 | LMNA (1.00) | LMNAMAPTSMN1; SMN2NPSR1USP2 | |
| Fluphenazine SCHEMBL7194249 | 0.99 | LMNA (0.98) | LMNAMAPTSMN1; SMN2NPSR1USP2 | |
| Fluphenazine SCHEMBL29388890 | 0.99 | LMNA (1.00) | LMNAMAPTSMN1; SMN2NPSR1USP2 | |
| Fluphenazine SCHEMBL29354183 | 0.99 | LMNA (1.00) | LMNAMAPTSMN1; SMN2NPSR1USP2 | |
| Fluphenazine SCHEMBL5072860 | 0.99 | LMNA (1.00) | LMNAMAPTSMN1; SMN2NPSR1USP2 | |
| Fluphenazine SCHEMBL19221 | 0.99 | LMNA (1.00) | LMNAMAPTSMN1; SMN2NPSR1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3406 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250090501-A1 | METHODS OF TREATING GUT MOTILITY DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-03-20 | — | — | US | claimed |
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | HOTH THERAPEUTICS, INC. | 2025-01-30 | — | — | US | claimed |
| EP-4460293-A2 | METHODS OF TREATING GUT MOTILITY DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-11-13 | — | — | EP | claimed |
| EP-4297868-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | Hoth Therapeutics, Inc. (US) | 2024-01-03 | — | — | EP | claimed |
| US-20230346879-A1 | COMPOSITIONS AND METHODS FOR COMBINATORIAL DRUG DISCOVERY IN NANOLITER DROPLETS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2023-11-02 | — | — | US | claimed |
| CN-116546960-A | Senescent cell lysis compounds and compositions | 努奇多有限公司 | 2023-08-04 | — | — | CN | claimed |
| WO-2023130149-A2 | METHODS OF TREATING GUT MOTILITY DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-07-06 | — | — | WO | claimed |
| WO-2022182658-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | HOTH THERAPEUTICS, INC. (US) | 2022-09-01 | — | — | WO | claimed |
| CN-113209050-A | Long-acting in vivo skin-embedded or implanted sustained-release preparation based on biocompatible polymer | 浙江恒冀制药有限责任公司 | 2021-08-06 | — | — | CN | claimed |
| US-20200353033-A1 | COMPOSITIONS AND METHODS FOR COMBINATORIAL DRUG DISCOVERY IN NANOLITER DROPLETS | THE BROAD INSTITUTE, INC. (US) | 2020-11-12 | — | — | US | claimed |
| WO-1999026661-A1 | A COVALENT CONJUGATE OF CLOZAPINE WITH A FATTY ACID AND ITS USE FOR TREATING SCHIZOPHRENIA | PROTARGA INC. (US) | 1999-06-03 | — | — | WO | claimed |
| US-5703101-A | Agonist-antagonist combination to reduce the use of nicotine and other drugs | Schaap, Robert J. | 1997-12-30 | — | — | US | claimed |
| EP-0741570-A1 | METHOD FOR PREVENTING OR REDUCING PHOTOSENSITIVITY AND/OR PHOTOTOXICITY REACTIONS TO MEDICATIONS | G.D. SEARLE & CO. (US) | 1996-11-13 | — | — | EP | claimed |
| WO-1995020387-A1 | METHOD FOR PREVENTING OR REDUCING PHOTOSENSITIVITY AND/OR PHOTOTOXICITY REACTIONS TO MEDICATIONS | G.D. SEARLE & CO. (US) | 1995-08-03 | — | — | WO | claimed |
| US-4938758-A | Anti-pathogenic blood collection system and method | AL SIOUFI HABIB (US) | 1990-07-03 | — | — | US | claimed |
| EP-0180364-B1 | PHARMACEUTICAL COMPOSITIONS CONTAINING PHENOTHIAZINES | RECKITT AND COLMAN PRODUCTS LIMITED (GB) | 1990-03-07 | — | — | EP | claimed |
| EP-0263873-A4 | ANTI-PATHOGENIC BLOOD COLLECTION SYSTEM AND METHOD. | AL-SIOUFI HABIB | 1989-07-11 | — | — | EP | claimed |
| EP-0263873-A1 | ANTI-PATHOGENIC BLOOD COLLECTION SYSTEM AND METHOD | AL-SIOUFI, Habib (US) | 1988-04-20 | — | — | EP | claimed |
| WO-1987006119-A1 | ANTI-PATHOGENIC BLOOD COLLECTION SYSTEM AND METHOD | AL SIOUFI HABIB | 1987-10-22 | — | — | WO | claimed |
| EP-0180364-A2 | Pharmaceutical compositions containing phenothiazines | RECKITT AND COLMAN PRODUCTS LIMITED (GB) | 1986-05-07 | — | — | EP | claimed |